Table 3. Univariate and multivariate analyses of clinicopathologic factors associated with response to NAC.
| Factor | N | Response rate (%) | Univariate | Multivariate |
|---|---|---|---|---|
| P valueaOR (95% CI) | P valueaOR (95% CI) | |||
| Age (years) | ||||
| ≤ 65 | 42 | 56.1 | 0.102 | 0.154 |
| > 65 | 41 | 38.1 | 2.07 (0.86–4.99) | 2.02 (0.77–5.33) |
| Smoking status | ||||
| Never or Mild | 38 | 39.5 | 0.209 | |
| Heavy | 45 | 53.3 | 1.75 (0.73–4.20) | |
| Alcohol status | ||||
| Never or Moderate | 43 | 48.8 | 0.726 | |
| Heavy | 40 | 45.0 | 0.86 (0.36–2.03) | |
| Performance status | ||||
| 0 | 75 | 48.0 | 0.574 | |
| 1 or 2 | 8 | 37.5 | 0.65 (0.15–2.92) | |
| Differentiation | ||||
| Well | 30 | 50.0 | 0.679 | |
| Moderately or poorly | 53 | 45.3 | 1.21 (0.49–2.96) | |
| T classification | ||||
| T2 | 15 | 46.7 | 0.978 | 0.628 |
| T3-4 | 68 | 47.1 | 1.02 (0.33–3.11) | 0.73 (0.20–2.60) |
| N classification | ||||
| N0-1 | 23 | 65.2 | 0.043 | 0.031 |
| N2-3 | 60 | 40.0 | 0.36 (0.13–0.98) | 0.29 (0.09–0.89) |
| NAC categories | ||||
| PF | 45 | 48.9 | 0.706 | |
| TPF | 38 | 44.7 | 0.84 (0.36–2.01) | |
| HLA class I | ||||
| High | 14 | 57.1 | 0.407 | |
| Low | 69 | 44.9 | 0.61 (0.19–1.95) | |
| PD-L1 | ||||
| Positive | 26 | 53.8 | 0.399 | 0.591 |
| Negative | 57 | 43.9 | 0.67 (0.26–1.70) | 0.73 (0.24–2.26) |
| CD3 | ||||
| High | 41 | 58.5 | 0.039 | 0.378 |
| Low | 42 | 35.7 | 0.39 (0.16–0.95) | 0.61 (0.20–1.82) |
| CD4 | ||||
| High | 41 | 51.2 | 0.446 | 0.711 |
| Low | 42 | 42.8 | 0.71 (0.30–1.70) | 0.81 (0.28–2.39) |
| CD8 | ||||
| High | 41 | 63.4 | 0.004 | 0.039 |
| Low | 42 | 31.0 | 0.26 (0.10–0.64) | 0.32 (0.11–0.95) |
aLogistic regression analysis; OR, odds ratio; CI, confidence interval; NAC, neoadjuvant chemotherapy; PF, cisplatin and 5-fluorouracil; TPF, docetaxel, cisplatin, and 5-fluorouracil.